Last Wednesday, members of Egetis’ management team and invited key opinion leaders provided an update and review of Egetis' strategy and pipeline. The presentations focused on the unmet medical need, development plans, pre-launch activities and commercialization plans for the investigational drug tiratricol, being developed as a possible treatment for MCT8 deficiency, as well as additional activities to create and enhance long-term shareholder value. Replay from December 18.

info@redeye.se (Redeye.se)

Redeye AB - Redeye.se